PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial

Contributed by: Business Wire

Tags

Research
FDA
Clinical Trials
Stem Cells
Biotechnology
Managed Care
Health
Pharmaceutical
Science
PK MED

More Like This

PK MED Receives €1.5M DeepTech Non-Dilutive Financing From Bpifrance for the Development of a Local Cell-Homing Implant to Enhance Bone Marrow Transplantation

PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants

PR Newswire associated0

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

PR Newswire associated0

Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

PR Newswire associated0

Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

Business Wire logo

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis

4Moving Biotech completes enrollment in Phase 2a INFLAM MOTION study evaluating first-in-class intra-articular GLP-1 therapy targeting synovitis as a driver of pain and disease progression in knee osteoarthritis

4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics